Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats

L. Sedláková, S. Kikerlová, Z. Husková, L. Červenková, VČ. Chábová, J. Zicha, JR. Falck, JD. Imig, E. Kompanowska-Jezierska, J. Sadowski, V. Krátký, L. Červenka, L. Kopkan,

. 2018 ; 38 (5) : . [pub] 20180912

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028299

Grantová podpora
NV15-25396A MZ0 CEP - Centrální evidence projektů

We hypothesized that vascular actions of 20-hydroxyeicosatetraenoic acid (20-HETE), the product of cytochrome P450 (CYP450)-dependent ω-hydroxylase, potentiate prohypertensive actions of angiotensin II (ANG II) in Cyp1a1-Ren-2 transgenic rats, a model of ANG II-dependent malignant hypertension. Therefore, we evaluated the antihypertensive effectiveness of 20-HETE receptor antagonist (AAA) in this model. Malignant hypertension was induced in Cyp1a1-Ren-2 transgenic rats by activation of the renin gene using indole-3-carbinol (I3C), a natural xenobiotic. Treatment with AAA was started either simultaneously with induction of hypertension or 10 days later, during established hypertension. Systolic blood pressure (SBP) was monitored by radiotelemetry, indices of renal and cardiac injury, and kidney ANG II levels were determined. In I3C-induced hypertensive rats, early AAA treatment reduced SBP elevation (to 161 ± 3 compared with 199 ± 3 mmHg in untreated I3C-induced rats), reduced albuminuria, glomerulosclerosis index, and cardiac hypertrophy (P<0.05 in all cases). Untreated I3C-induced rats showed augmented kidney ANG II (405 ± 14 compared with 52 ± 3 fmol/g in non-induced rats, P<0.05) which was markedly lowered by AAA treatment (72 ± 6 fmol/g). Remarkably, in TGR with established hypertension, AAA also decreased SBP (from 187 ± 4 to 158 ± 4 mmHg, P<0.05) and exhibited organoprotective effects in addition to marked suppression of kidney ANG II levels. In conclusion, 20-HETE antagonist attenuated the development and largely reversed the established ANG II-dependent malignant hypertension, likely via suppression of intrarenal ANG II levels. This suggests that intrarenal ANG II activation by 20-HETE is important in the pathophysiology of this hypertension form.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028299
003      
CZ-PrNML
005      
20220530145925.0
007      
ta
008      
190813s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1042/BSR20171496 $2 doi
035    __
$a (PubMed)30054426
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Sedláková, Lenka, $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $d 1992- $7 xx0273377
245    10
$a 20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats / $c L. Sedláková, S. Kikerlová, Z. Husková, L. Červenková, VČ. Chábová, J. Zicha, JR. Falck, JD. Imig, E. Kompanowska-Jezierska, J. Sadowski, V. Krátký, L. Červenka, L. Kopkan,
520    9_
$a We hypothesized that vascular actions of 20-hydroxyeicosatetraenoic acid (20-HETE), the product of cytochrome P450 (CYP450)-dependent ω-hydroxylase, potentiate prohypertensive actions of angiotensin II (ANG II) in Cyp1a1-Ren-2 transgenic rats, a model of ANG II-dependent malignant hypertension. Therefore, we evaluated the antihypertensive effectiveness of 20-HETE receptor antagonist (AAA) in this model. Malignant hypertension was induced in Cyp1a1-Ren-2 transgenic rats by activation of the renin gene using indole-3-carbinol (I3C), a natural xenobiotic. Treatment with AAA was started either simultaneously with induction of hypertension or 10 days later, during established hypertension. Systolic blood pressure (SBP) was monitored by radiotelemetry, indices of renal and cardiac injury, and kidney ANG II levels were determined. In I3C-induced hypertensive rats, early AAA treatment reduced SBP elevation (to 161 ± 3 compared with 199 ± 3 mmHg in untreated I3C-induced rats), reduced albuminuria, glomerulosclerosis index, and cardiac hypertrophy (P<0.05 in all cases). Untreated I3C-induced rats showed augmented kidney ANG II (405 ± 14 compared with 52 ± 3 fmol/g in non-induced rats, P<0.05) which was markedly lowered by AAA treatment (72 ± 6 fmol/g). Remarkably, in TGR with established hypertension, AAA also decreased SBP (from 187 ± 4 to 158 ± 4 mmHg, P<0.05) and exhibited organoprotective effects in addition to marked suppression of kidney ANG II levels. In conclusion, 20-HETE antagonist attenuated the development and largely reversed the established ANG II-dependent malignant hypertension, likely via suppression of intrarenal ANG II levels. This suggests that intrarenal ANG II activation by 20-HETE is important in the pathophysiology of this hypertension form.
650    _2
$a amidy $x farmakologie $7 D000577
650    _2
$a angiotensin II $x metabolismus $7 D000804
650    _2
$a blokátory receptorů AT1 pro angiotensin II $x farmakologie $7 D047228
650    _2
$a zvířata $7 D000818
650    _2
$a antihypertenziva $x farmakologie $7 D000959
650    _2
$a cytochrom P-450 CYP1A1 $x genetika $7 D019363
650    _2
$a kyseliny hydroxyeikosatetraenové $x antagonisté a inhibitory $x metabolismus $7 D006893
650    _2
$a hypertenze maligní $x chemicky indukované $x farmakoterapie $x metabolismus $7 D006974
650    _2
$a indoly $x toxicita $7 D007211
650    _2
$a ledviny $x účinky léků $x metabolismus $7 D007668
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a potkani transgenní $7 D055647
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kikerlová, Soňa, $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $d 1978- $7 xx0256886
700    1_
$a Husková, Zuzana $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Červenková, Lenka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Chábová, Věra Čertíková $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Zicha, Josef $u Institute of of Physiology, Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Falck, John R $u Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, U.S.A.
700    1_
$a Imig, John D $u Department of Pharmacology and Toxicology, Medical College of Wisconsin, WI, U.S.A.
700    1_
$a Kompanowska-Jezierska, Elżbieta, $u Department of Renal and Body Fluid Physiology, M. Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland. $d 1959- $7 xx0273376
700    1_
$a Sadowski, Janusz $u Department of Renal and Body Fluid Physiology, M. Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland.
700    1_
$a Krátký, Vojtěch $7 xx0249394 $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Červenka, Luděk $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Kopkan, Libor $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic libor.kopkan@ikem.cz.
773    0_
$w MED00000783 $t Bioscience reports $x 1573-4935 $g Roč. 38, č. 5 (2018)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30054426 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20220530145923 $b ABA008
999    __
$a ok $b bmc $g 1433448 $s 1066759
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 38 $c 5 $e 20180912 $i 1573-4935 $m Bioscience reports $n Biosci Rep $x MED00000783
GRA    __
$a NV15-25396A $p MZ0
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace